PO.TB07.02 · 肿瘤生物学

eIF4A1在三阴性乳腺癌中对癌症干性的直接调控

Direct regulation of the cancer stemness by eIF4A1 in triple-negative breast cancer

海报缩略图:eIF4A1在三阴性乳腺癌中对癌症干性的直接调控
编号 2187 展板 6 时间 4/20 09:00–12:00 区域 Section 30 主讲 Azeezat Osikoya, BS
分会场 Metabolic and Transcriptional Control of Cancer Stem Cell Plasticity
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Azeezat Oluwatobiloba Osikoya, Shobhit Srivastava, David Terrero, Dayanidhi Raman

Cell and Cancer Biology, College of Medicine & Life Sciences, University of Toledo-Health Science Campus, Toledo, OH

摘要 Abstract

中文摘要
三阴性乳腺癌(TNBC)极具侵袭性,化疗后易复发,并因转移导致高死亡率。尽管对新辅助化疗(NACT)有初始反应,但常常复发导致化疗耐药。既往证据指向一小群化疗耐药的肿瘤起始细胞,称为乳腺癌干样细胞(BCSCs)。这些细胞表现出内在的耐药性和自我更新能力,由SOX2、OCT4、NANOG和KLF4等多能性转录因子(PTFs)驱动。BCSCs在NACT后存活,导致微小残留病灶(MRD),这是一种具有重要临床意义的肿瘤持续存在状态,可播种复发、侵袭性再生长和转移。我们此前的研究鉴定出真核翻译起始因子4A1(eIF4A1)是TNBC中癌症干性的重要调控因子。在此,我们研究eIF4A1解旋酶活性调控癌症干性从而促进MRD的机制基础。为确立临床相关性,我们分析了人TNBC生物样本及配对的邻近正常组织的PTFs表达。为在体外证明eIF4A1在维持癌症干性中的因果作用,通过CRISPR/Cas9生成的eIF4A1敲除(KO)TNBC细胞经野生型(WT)-eIF4A1及其解旋酶缺陷突变体的异位表达进行回补。通过免疫印迹和qPCR评估PTFs的表达,而癌症干性的度量则通过ALDH活性、肿瘤球形成、锚定非依赖性生长和3D生长实验进行评估。为直接确定eIF4A1对PTFs的翻译调控,我们采用荧光素酶报告系统,通过对SOX2、OCT4、NANOG和KLF4 mRNA的5′非翻译区(UTRs)的突变分析,测量eIF4A1依赖性翻译。在TNBC中观察到显著更高的eIF4A1和PTF蛋白水平,而在邻近正常区域则较低。与之一致,在eIF4A1-KO背景下异位表达WT-eIF4A1强有力且显著地回补了PTF表达、肿瘤球形成效率、Matrigel上的3D集落生长和锚定非依赖性生长。解旋酶缺陷突变体未能恢复PTF水平和干性特征。此外,总ALDH活性和某些ALDH异构体的表达也呈现相似趋势。对PTFs的WT或突变5′-UTRs进行克隆并分析报告荧光素酶活性,证实eIF4A1可直接调控PTF mRNA的翻译,进而调控PTF驱动的癌症干性程序。我们的发现首次证明eIF4A1解旋酶活性通过促进含结构化5′ UTRs的PTF mRNA的翻译,直接主导TNBC中的癌症干性程序。正在进行的研究正在评估体内肿瘤起始频率。因此,靶向eIF4A1的解旋酶活性可能抑制癌症干性、恢复对治疗的敏感性、减少复发并延长TNBC患者的生存期。
查看英文原文 English abstract
Triple-negative breast cancer (TNBC) is very aggressive with relapses after chemotherapy and high mortality due to metastases. Though there is an initial response to neoadjuvant chemotherapy (NACT) it frequently recurs leading to chemoresistance. Prior evidence points to a small population of chemoresistant tumor-initiating cells termed breast cancer stem-like cells (BCSCs). These cells exhibit intrinsic drug resistance and self-renewal capacity driven by pluripotency transcription factors (PTFs) such as SOX2, OCT4, NANOG, and KLF4. BCSCs survive following NACT, resulting in minimal residual disease (MRD), a clinically significant state of tumor persistence that seeds relapse, aggressive regrowth and metastasis. Our prior studies identified eukaryotic translation initiation factor 4A1 (eIF4A1) as an important regulator of cancer stemness in TNBC. Here, we investigate the mechanistic basis by which eIF4A1 helicase activity regulates cancer stemness that promotes MRD. To establish clinical relevance, we analyzed human TNBC biospecimens and matched adjacent normal tissues for PTFs expression. To demonstrate a causative role for eIF4A1 in sustaining cancer stemness in vitro , eIF4A1-knockout (KO) TNBC cells generated by CRISPR/Cas9 were rescued by ectopic expression of wild type (WT)-eIF4A1 and its helicase-defective mutants. Expression of PTFs was assessed by immunoblotting and qPCR, while measures of cancer stemness were evaluated by ALDH activity, tumorsphere formation, anchorage-independent growth, and 3D growth assays. To directly determine translational regulation of PTFs by eIF4A1, we employed a luciferase reporter system to measure eIF4A1-dependent translation through mutational analysis of 5′ untranslated regions (UTRs) of SOX2, OCT4, NANOG and KLF4 mRNAs. A significantly higher eIF4A1 and PTF protein levels were observed in TNBC but lower in adjacent normal area. Consistent with this, ectopic WT-eIF4A1 in the eIF4A1-KO background robustly significantly rescued PTF expression, tumorsphere formation efficiency, 3D-colony growth on Matrigel, and anchorage-independent growth. The helicase-defective mutants failed to restore PTF levels and stemness traits. Furthermore, total ALDH activity and expression of some ALDH isoforms followed a similar trend. Cloning of WT or mutant 5′-UTRs of PTFs and analysis of reporter luciferase activity confirmed that eIF4A1 can directly regulate the translation of PTF mRNAs and hence the PTF-driven cancer stemness program. Our findings demonstrate for the first time that eIF4A1 helicase activity directly governs a cancer stemness program in TNBC by promoting translation of PTF mRNAs harboring structured 5′ UTRs. Ongoing studies are assessing tumor initiation frequency in vivo . Thus, targeting the helicase activity of eIF4A1 may suppress cancer stemness, restore sensitivity to therapy, reduce relapses and improve longevity in TNBC.
利益披露 Disclosure
A. O. Osikoya, None.. S. Srivastava, None.. D. Terrero, None.. D. Raman, None.

← 返回 AACR 2026 检索